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We have shown previously that genetically engineered Mengo viruses with artificial deletions in their 5* noncoding
polyribocytidylic acid (poly(C)) tracts are highly attenuated for the natural murine host and also for other animals such as
baboons, macaques, and domestic pigs. The present report further characterizes select short poly(C) tract Mengo viruses
in the natural murine host. A positive correlation was found between the length of the poly(C) tract and murine virulence,
as measured by virus brain titers and brain lesion scores after infection. Histological examination of brain tissue collected
from infected animals clearly showed that the short poly(C) tract viruses did not induce the devastating pathological
effects characteristic of animals inoculated with wild-type virus. Instead, the short-tract Mengo viruses proved excellent
immunological agents. A dose of only 100 plaque-forming units of vMC24 (poly(C) tract: C13UC10), injected subcutaneously,
protected 80% of recipient animals against a normally lethal dose of encephalomyocarditis virus. The protection was long-
lived, and animals similarly immunized with vMC0 virus (poly(C) tract: C0) still had protective neutralizing antibody titers up
to 16 months after inoculation. In addition, the short-tract viruses proved genetically stable, in that the vMC24 virus did not
yield detectable pathogenic revertants even after multiple, forced passages in 4-week-old mice. These studies suggest that
Mengo viruses containing deletions in their poly(C) tracts are biologically safe and potent immunogens and imply that they
may have uses as cardiovirus vaccines. q 1996 Academic Press, Inc.
INTRODUCTION late, and it has also been observed that a few uridine
or guanidine residues may occasionally disrupt the
The encephalomyocarditis-like cardioviruses are posi- homopolymer. The Mengo (M strain) poly(C), for exam-
tive-strand RNA viruses (family: Picornaviridae) with a ple, spans 55 nucleotides with a single uridine discon-
worldwide distribution. Encephalomyocarditis virus tinuity (C44UC10), while the tract in EMCV (Rueckert
(EMCV), the best characterized member, was originally strain) is longer and has three uridine breaks (C115U-
isolated from a chimpanzee in 1945 (Helwig et al., 1945). CUC3UC10) (Duke et al., 1992). In some aphthoviruses,
Since then, many other serologically related strains have uninterrupted poly(C) segments of up to 420 nucleo-
been described, including Mengo, Columbia-SK, and tides have been documented (Black et al., 1979; Esc-
Maus Elberfeld viruses. Studies have shown that infec- armis et al., 1992; Porter et al., 1974).
tion and disease due to EMC-like viruses is common in Although the biological function of the viral poly(C)
many species of wild and domestic animals (Grainer, tracts is not entirely clear, our studies with Mengo
1961; Gainer et al., 1961; Gainer, 1967). EMCV clinical virus have shown that this region is a major determi-
disease in humans is rare, although piggeries, primate nant of viral pathogenicity (Duke et al., 1990; Martin
colonies, and zoological gardens, among others, have et al., 1996). Mengo viruses derived from cDNA clones
suffered tragic and costly losses due to EMCV infection grew indistinguishably in single-step growth experi-
(Zimmerman, 1994). ments regardless of tract size. But when tested in 4-
An unusual characteristic of EMCV-like viruses that week-old mice, the viruses with shortened poly(C)
is shared by members of the aphthoviruses is the pres- tracts were dramatically attenuated for virulence rela-
ence of a homopolymeric, polyribocytidylic acid (po- tive to the wild-type virus or to a genetically engi-
ly(C)) tract within the 5* untranslated sequences (Black neered virus with the wild-type poly(C) tract length
et al., 1979; Perez-Bercoff et al., 1977). These peculiar (Duke et al., 1990; Martin et al., 1996; Palmenberg et
poly(C) tracts are retained with fidelity during virus al., 1994). In mice and other mammals, the short-tract
growth in tissue culture and also during passage in Mengo viruses induced protective anti-EMCV antibody
animals (Brown et al., 1974). Among characterized viral responses, suggesting that these isolates could po-
strains, the specific tract length may vary for each iso- tentially serve as live, attenuated vaccines against all
cardioviruses of the EMCV serotype (Duke et al., 1990;
Osorio et al., 1996). It has been further demonstrated1 To whom correspondence and reprint requests should be ad-
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offering the additional possibility of novel, recombi- ert et al., 1981), resuspended in a small volume of PBSA
(PBS with 0.1% BSA), and then retitered in HeLa cells.nant vaccine vectors (Altmeyer et al., 1994; Altmeyer
et al., 1995).
Histological evaluationWe now report an expanded characterization of short-
tract Mengo viruses in the natural murine host. Specifi- One-hundred-eighty 4-week-old Swiss/ICR mice were
cally, Mengo viruses containing progressive deletions inoculated intracerebrally with 104 PFU of vMwt, vMC24 ,in the poly(C) region were comparatively evaluated for
vMD3C0D10, or PBSA (20 ml). On Days 0– 7, 10, and 15neurovirulence, brain histopathology, and virus brain ti-
PI, five animals from each group were sacrificed and
ters. Dose effects and long-term antibody responses
their brain tissues harvested. Tissue sections were fixed
were also used to assess the immunogenic potential of
in 10% formalin, stained with hematoxylin and eosin, and
different virus strains. In addition, we have tested the
then evaluated microscopically for histological changes
reversion potential of a short-tract virus during serial
relative to tissues from mock-inoculated animals. A score
brain passages in 4-week-old mice.
system, ranging from uninfected/normal (0) to severe
meningoencephalitis (///), was used to record the rel-
MATERIALS AND METHODS ative severity of virus-induced lesions.
Animals
Minimal protection dose studies
One- to 2-day-old, and 4- to 6-week-old BALB/c and Groups of three to five 4-week-old Swiss/ICR mice
Swiss/ICR female mice were obtained from breeding col- were inoculated subcutaneously (sc) with 1, 10, 102, 103,
onies at the Department of Animal Health and Biomedical or 104 PFU of vMC24 . Blood samples were collected fromSciences (University of Wisconsin) and the National Wild- the retro-orbital sinus of each animal before inoculation
life Research Center (Madison, WI). and at 10, 20, and 30 days PI and then assayed for the
presence of neutralizing antibody against vMwt (Sherry
Viruses et al., 1986). At 40 days PI, the animals were challenged
with 106 PFU of EMCV-R by intraperitoneal (ip) inocula-Stocks of EMCV Rueckert strain (EMCV-R) and Mengo
tion. This dose of EMCV is 103 LD50 as administeredM strain (Mengo-M) virus were amplified in HeLa cells
by this route.and concentrated as described (Rueckert et al., 1981).
Recombinant cDNA plasmids, pMwt, pMC24 , pMC0, and
Long-term vaccine studiespMD3C0D10 with full-length copies of infectious Mengo
sequences have been described (Duke et al., 1989; Pal- Groups of five 4- to 6-week-old BALB/c mice were
menberg et al., 1994; Martin et al., 1996). Progeny viruses injected (ip) with 50, 5 1 102, or 5 1 103 PFU of vMC0 .
were amplified from plaques obtained after HeLa cell A control group received PBSA only, by the same route.
transfections with T7 RNA transcripts derived from these Blood samples were collected from all animals before
plasmids (Hahn et al., 1995). The infected HeLa cell cul- inoculation, at 2 weeks, and at 1, 3, 6, and 16 months PI
tures were clarified by low-speed centrifugation, and the and assayed for the presence of anti-Mengo neutralizing
supernatants were titered in standard plaque assays be- antibody. Surviving animals were challenged at 16
fore each experiment. months PI with 3 1 105 PFU of EMCV-R (i.e., 103 LD50
doses) by ip inoculation.
Virus brain titer assays
Serial passage in 4-week-old mice
Thirty-five 4-week-old Swiss/ICR mice were inoculated
in the left cerebral hemisphere (ic) with vMD3C0D10 Ten 4-week-old Swiss/ICR mice were injected ic with
104 PFU of vMC24 . At 4 days PI, the animals were sacri-(dose: 104 plaque-forming units, PFU). At 0– 7, 10, and
15 days postinoculation (PI), groups of five animals were ficed, their brains were removed aseptically, and sam-
ples were pooled as homogenate suspensions in PBSAeuthanized, and the right cerebral hemisphere of each
animal was recovered aseptically, weighed, and homog- (10% w/v). Following centrifugation (10,000 rpm for 30
min), supernatants were removed, aliquoted, titered, andenized as a 10% suspension in 0.1% bovine serum albu-
min (BSA) in sterile water (w/v). After pelleting of cell then designated as passage-1 virus stock (vMC24P1). To
ensure sufficient virus for a second passage, samplesdebris by centrifugation (10,000 g for 30 min at 47C),
homogenant supernatants were serially diluted and tit- of this P1 stock were amplified once in HeLa cells (0.1
PFU/cell multiplicity of infection). The HeLa-derived su-ered for virus on HeLa cell monolayers as described
(Rueckert et al., 1981). If virus was not detected in an pernatants (104 PFU) were then injected ic into 10 more 4-
week-old Swiss/ICR mice. These animals likewise wereundiluted sample (0.1 ml), a parallel sample (1 ml) was
reconcentrated by centrifugation through a cushion of sacrificed at 4 days PI, and virus was extracted from
their brains as in passage 1. This resultant stock was30% sucrose in phosphate-buffered saline (PBS) (Rueck-
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TABLE 1designated vMC24P2. Three additional serial passages
were conducted with the same protocol (i.e., vMC24P3, Poly(C) Tract Length and Brain Lesion Score in Swiss/ICR Mice
vMC24P4, and vMC24P5 viruses). Each stock of passaged
Severity of brain lesionsbvirus (P1 –P5) was tested for titer and for plaque morphol-
Daysogy in standard plaque assays with HeLa monolayers.
postinoculationa vMwt vMC24 vMD3COD10In addition, the relative virulence of these viruses was
evaluated over several weeks after ic inoculation of 104 0 0c 0 0
PFU into 4-week-old Swiss/ICR mice. 1 /d 0 0
2 / {e 0
3 //f / 0
RESULTS 4 // // 0
5 ///g / {
Virus titer in brain samples 6 /// { 0
7 Dead { 0
The potential role of poly(C) tract length in the neurovi- 15 Dead { 0
rulence of Mengo virus was evaluated by comparing the
a Inoculation (ic) with 104 PFU of virus.brain titers of vMD3C0D10, vMC24 , and vMwt viruses
b Average score for four animals after hematoxylin and eosin stainingafter ic inoculation. As reported previously (Duke et al.,
of formalin-fixed brain tissue and microscopic examination.1990), after an ic dose of 104 PFU of vMwt, the average c No visible changes.
virus brain titer in the uninoculated hemisphere in- d Meningitis.
creased rapidly, reaching levels (⁄106 PFU/ml of 10% e Minor changes in cell population.
f Meningitis, infiltration of PMN leukocytes, macrophages, and lym-brain suspension) that remained high until animal death
phocytes.at 6– 7 days PI (Fig. 1). In contrast, the brain titers from
g Meningitis, diffuse encephalitis, and neuronal death.animals receiving short poly(C) tract viruses did not in-
crease as rapidly. On Day 1 PI, for example, the mean
respectively. Thereafter, the titers of both short-tract vi-brain titers for vMC24 and vMD3C0D10 were only 2 1
ruses declined quickly in all animals, and infectivity was102 and 103 PFU/ml, respectively (Fig. 1).
undetectable at 7 days PI with the shortest tract virus,A second indicator affected by poly(C) length was the
and after 15 days with the vMC24 virus. Nevertheless,relative maxima of brain titer reached by these viruses
even for vMD3C0D10, the maximum titers reached byduring the assay. Inoculation with vMwt gave mean brain
these animals generally met or exceeded the theoreticaltiters which peaked at 4 1 107 PFU/ml on Days 5– 6
amount of input inoculum (assuming 100% recovery), pro-PI, whereas vMC24 and vMD3C0D10 reached maximum
viding evidence of some viral replication, albeit at lowtiters of 8 1 104 and 103 PFU/ml on Days 5 and 2 PI,
levels.
Histological studies
The brain tissues of animals infected with vMwt devel-
oped significant histological lesions. Acute leptomen-
ingitis was detectable as early as Day 1 PI (Table 1), and
the severity of these lesions increased progressively over
time to include infiltration of polymorphonuclear leuko-
cytes, macrophages, and lymphocytes. In addition, ne-
crotic changes such as hyperchromatosis, pyknosis, nu-
clear fragmentation, and karyorrhexis of groups of nerve
cells were detected by 5 – 6 days PI (Fig. 2B). In contrast,
by Day 4 PI, the vMC24 virus had produced only a mild
meningoencephalitis with minimal neuronal death and
cellular infiltration (Fig. 2C). Infection with vMD3C0D10
gave no detectable meningitis or other encephalitis-as-
sociated changes that could be detected by general mi-
FIG. 1. Mean brain titer with standard deviation of Mengo viruses. croscopy (Table 1), and the brain tissues from these ani-Three groups of thirty-five 4-week-old, female mice were inoculated
mals were usually indistinguishable from those of con-(ic) with 104 PFU of vMwt (denoted with squares), vMC24 (circles), and
trols (compare Fig. 2D with 2A).vMD3C0D10 (triangles). Five animals from each group were euthanized
at indicated times and virus brain titers measured as described under
Materials and Methods. The filled symbols represent animals that died Protective dose studies
from infection. The dashed line is the theoretical maximum recovery
The murine antibody responses against low doses offrom this inoculum. The vMwt and vMC24 data are from Duke et al.
(1990). vMC24 , as a representative of the short poly(C) viruses,
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FIG. 2. Brain histology. Four-week-old mice were inoculated with 104 PFU of virus and harvested at 4 days PI. Sections of the cerebrum were
stained with hematoxylin and eosin stain, and are shown at 2001 magnification. (A) Section from a PBSA-injected animal (control). (B) Section from
a vMwt-inoculated animal with an acute meningitis. (C) Section from a vMC24-infected mouse with mild meningitis. (D) Section from a mouse injected
with vMD3C0D10 showing the lack of detectable histopathology.
were examined after subcutaneous inoculation. Two of five mice immunized with 102 PFU developed neutralizing
antibodies, as did one of five animals receiving either 1the three animals receiving 103 PFU responded with sig-
nificant levels of neutralizing antibody that were readily or 10 PFU. Upon challenge with EMCV at 40 days PI, all
animals that exhibited any level of neutralizing titer weredetectable within 10 days PI (Table 2). The third animal
from this group also produced neutralizing antibody but protected against pathology (symptoms) and death. The
animals that failed to seroconvert (titers  20) died ofat a reduced titer, detected only after 20 days PI. Of the
animals receiving even lower viral doses, four of the EMCV-like disease within 2 weeks after challenge.
TABLE 2
Neutralizing Antibody Induction by vMC24 in Swiss/ICR Mice
Dose of inoculum (subcutaneous)
1 PFU 10 PFU 100 PFU 1000 PFU 10,000 PFU
Days (PI)a Number b Titer c Number Titer Number Titer Number Titer Number Titer
10 0/5 20 0/5 20 0/5 20 2/3 80 5/5 20 – 160
20 0/5 20 1/5 20 4/5 20 – 80 3/3 20 –320 5/5 40 – 640
30 1/5 40 1/5 20 4/5 40 – 160 3/3 40 –1280 5/5 80 – 1280
Survived EMCV
challenged 1/5 na 1/5 na 4/5 na 3/3 na 5/5 na
a On Day 0 PI, groups of Swiss/ICR mice were inoculated with vMC24 .
b Number of animals in each group with detectable neutralizing titer against vMwt.
c Range of observed titers: reciprocal of lowest serum dilution that neutralized 500 PFU of vMwt in a plaque assay.
d Survival at least 2 weeks after Day 40 challenge with EMCV. na, not applicable.
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TABLE 3
Neutralizing Antibody Induction by vMC0 in BALB/C Mice
Dose of inoculum (intraperitoneal)
0 PFU 50 PFU 500 PFU 5000 PFU
Days (PI)a Numberb Titer c Number Titer Number Titer Number Titer
24 0/5 16 2/5 256–512 3/5 16 – 512 4/5 16 – 64
32 0/5 16 2/5 256–512 3/5 16 – 256 5/5 16 – 24
92 0/5 16 2/5 128–256 2/5 56 – 512 5/5 16 – 32
164 0/5 16 2/5 64 –256 2/5 128– 512 4/5 16 – 32
500 0/5 16 2/5 32 –256 1/4 512 3/4 16 – 32
Survived EMCV
challenged 0/5 na 3/5 na 2/4 na 3/4 na
a On Day 0 PI, groups of BALB/c mice were inoculated with vMC0 .
b Number of animals in each group with detectable neutralizing titer against vMwt.
c Range of observed titers: reciprocal of lowest serum dilution that neutralized 500 PFU of vMwt in a plaque assay.
d Survival at least 2 weeks after Day 500 challenge with EMCV. na, not applicable.
In a parallel study, BALB/c animals were tested for the DISCUSSION
duration of protection after receiving similarly low doses
We have previously shown that genetically engineeredof vMC0 virus. Again, 50 PFU (ip) were sufficient to allow
Mengo viruses with short poly(C) tracts are significantlytwo of five animals to seroconvert with detectable neu-
attenuated for virulence (LD50 , 7.9 1 106 PFU ic) whentralizing titers of 1:16 (Table 3). Higher doses of inocu-
compared to wild-type viruses (LD50 , 9 PFU ic) in 4-week-lum increased the relative number of respondent animals
old mice (Duke et al., 1990; Martin et al., 1996). Animalsto three in five for 5 1 102 PFU and five in five for 5 1
receiving sublethal doses of vMC24 developed high levels103 PFU, but did not necessarily increase each groups’
of neutralizing antibodies that protected against a nor-composite neutralizing titers. The specific dose response
mally lethal challenge of EMCV (Duke et al., 1990). Thedifferences for particular animals may have been due to
virulence, as measured by LD50 , correlated inversely withsimple experimental variation. Alternatively, their re-
poly(C) tract length (Martin et al., 1996). With this report,sponses could reflect subtle variations in the genotypes
we have now shown that virulence, as measured by dis-of tested virus (vMC24 versus vMC0), the mice (Swiss/
ease severity, is also inversely correlated to poly(C) tractICR versus BALB/c) used in these studies, or even a
length. Following intracerebral inoculation, a dose of 104reproducibility distinction between the routes of expo-
PFU of vMwt resulted in higher virus brain titers (106sure (subcutaneous versus ip). Nevertheless, over the
PFU/ml) than those detected in mice inoculated with sim-500-day duration of this experiment (Table 2), all animals
ilar doses of vMC24 or vMD3C0D10. Microscopic exami-that continued in the study (one died of natural causes
nation of formalin-fixed brain tissue sections also con-in each of the 5 1 102 and 5 1 103 PFU groups) and had
firmed that the neuropathogenic properties of these vi-developed detectable neutralizing titer (i.e., ⁄16) within
the first month PI were also protected from EMCV chal-
lenge 18 months after receiving their only exposure to
TABLE 4the short poly(C) tract virus.
Serial Passage of vMC24 in Swiss/ICR Mice
Serial passage in 4-week-old Swiss/ICR mice
Virus titer
Passagea (brain) Plaqueb LD50cThe reversion potential of vMC24 was evaluated after
number (PFU/ml) size (PFU)five cycles of forced serial passage in the brains of 4-
week-old mice. During each passage, the observed virus 1 2.6 1 104 Medium 104
brain titers never exceeded 104 PFU/ml, the same level 2 9 1 103 Medium 104
3 8.2 1 104 Medium 104expected for a typical, attenuated short poly(C) tract virus
4 1.6 1 104 Medium 104(see Fig. 1). Of the five tested passages of virus, none
5 2.0 1 104 Medium 104had a larger plaque size than the initial vMC24 virus,
which might be indicative of faster growing revertant vi- a Dose of 104 PFU, injected intracerebrally.
rus, nor did any of these stocks regain virulence to 4- b On HeLa cells. Average size of 2.3 mm after 30 hr.
c Determined in 4-week-old, female Swiss/ICR mice.week-old mice (Table 4).
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ruses was directly related to the poly(C) tract length. with an initially small tract (6– 35 nucleotides), again had
expanded its tract length upon passage in mice (to 75–The vMwt caused a diffuse panencephalitis with severe
lesions detectable as early as 1 day PI, whereas vMC24 140 bases) (McCahon, 1981; Rieder et al., 1993). In con-
trast, our short poly(C) tract Mengo isolates passagedinfection resulted only in a mild meningitis, and
vMD3C0D10 did not induce detectable histopathology. with fidelity both in cell culture and in mice. Five cycles
of direct serial brain passage of vMC24 failed to restoreThe immunogenic potential of the short poly(C) tract
viruses had been previously evaluated, but only after the virulence. Although passaged viruses were not rigor-
ously examined by sequence, we suspect no changesadministration of high doses via atypical routes (ic and
ip). Those studies showed that vMC24 was strongly immu- in poly(C) length occurred because of the attenuated phe-
notypes. Twenty cycles of direct passage in culturednogenic, with inoculated animals developing high titers
of anti-Mengo neutralizing antibodies. However, a more macrophages or HeLa cells (Duke et al., 1989) likewise
failed to revert the vMC24 tract length or its virulence.useful evaluation of potential vaccine efficacy was ob-
tained here by administering low doses of viruses and This dichotomy of tract reversion between FMDV and
Mengo remains unexplained, though potentially it mayusing an injection route more common for animal vac-
cines. Doses as low as 102 PFU, inoculated subcutane- have an origin in the high observed recombination fre-
quency observed among FMDVs (McCahon, 1991). Alter-ously, induced seroconversion in 80% of recipient ani-
mals. Every animal in this study with a detectable neu- natively, the short poly(C) Mengo viruses may simply be
phenotypically dominant and protectively vaccinate thetralizing serum titer (at least 1:20), was protected. These
results are consistent with recent data from a related host before pathogenic revertants can arise and become
established.chimeric Mengo virus, administered at similarly low
doses (Altmeyer et al., 1995). In that study, ip inoculation In either case it is clear that the genetically engineered
poly(C) mutations within the Mengo cDNAs have pro-of only 10 PFU of a vMC24-derived virus expressing a
portion of the nucleoprotein of lymphocytic choriomenin- duced stably attenuated virus strains that seem uniformly
unable to produce the devastating pathological effectsgitis virus (LCMV) protected more than 80% of recipient
BALB/c mice from ic challenge with virulent LCMV (Alt- of the wild-type viruses. Moreover, these strains also
exhibit superb immunogenicity and vaccine potential formeyer et al., 1995).
In our studies, using a wide range of inocula and long many mammalian species, including primates, and it is
possible that we can protectively and safely immunizeterms of observation, we have consistently measured the
durable persistence of neutralizing antibodies in animals nearly any animal that is subject to cardiovirus infection
(gazelles, camels, elephants, lions, etc.) (Zimmerman,receiving any of the short poly(C) tract viruses. Typically,
2– 3 log10 of neutralizing antibodies have been detected 1994).
after 2 years PI in a few animals receiving 104– 106 PFU
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